Abstracts tagged "Adalimumab"

Abstract Number: 2509 • 2014 ACR/ARHP Annual Meeting
ADAM-10 As a Tocilizumab Treatment Predictive Factor in Rheumatoid Arthritis
Takeo Isozaki, Sakiko Isojima, Takahiro Tokunaga, Masayu Umemura, Hidekazu Furuya, Ryo Yanai, Ryo Takahashi, Kuninobu Wakabayashi, Nobuyuki Yajima, Yusuke Miwa and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose :A disintegrin and metalloproteinases (ADAMs) are a family of transmembrane and secreted proteins. ADAM-10 has been reported to be the enzyme responsible for the…
Abstract Number: 502 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Use in Patients with Rheumatoid Arthritis Having Failed One Previous Anti-TNF Agent: Comparison with Adalimumab, Etanercept and Infliximab
Denis Choquette¹, Marie-Pier Payette¹, Jean-Pierre Raynauld¹, Jean-Pierre Pelletier², Louis Bessette³, Edith Villeneuve¹, Boulos Haraoui¹, Isabelle Fortin⁴, Marie-Anaïs Rémillard⁵, Diane Sauvageau¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ³Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ⁴Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁵Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose : Tocilizumab, as an intra-venous agent, has been approved for rheumatoid arthritis (RA) in Canada in April 30th, 2010. It was the sixth approved…
Abstract Number: 2427 • 2014 ACR/ARHP Annual Meeting
Attainment of Low Disease Activity Is Predictive of Maintenance of Disease Control upon Adalimumab Discontinuation for Two Years Following Combination Therapy in Japanese Patients with Early Rheumatoid Arthritis
Yoshiya Tanaka¹, Hisashi Yamanaka², Naoki Ishiguro³, Nobuyuki Miyasaka⁴, Katsuyoshi Kawana⁵, Katsutoshi Hiramatsu⁶, Aki Kuroki⁵ and Tsutomu Takeuchi⁷, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Abbvie, Tokyo, Japan, ⁶Medical, Abbvie, Tokyo, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Although available data has suggested successful withdrawal of a monoclonal antibody TNF blocker after achieving low disease activity (LDA) or remission over the short-term…
Abstract Number: 500 • 2014 ACR/ARHP Annual Meeting
Prediction of Successful Dose Reduction or Discontinuation of Adalimumab or Etanercept Using Serum Drug Levels and Antidrug Antibody Measurement
Noortje van Herwaarden¹, Chantal Bouman², Aatke van der Maas³, Ronald F. van Vollenhoven⁴, Johannes W.J. Bijlsma⁵, Frank H.J. van den Hoogen⁶, Alfons A. den Broeder¹ and Bart van den Bemt⁷, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³Hengstdal 3, Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ⁵Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ⁷Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose Dose reduction and discontinuation of TNF inhibitors (TNFi) is feasible in many rheumatoid arthritis (RA) patients, but leads to (temporary) worsening of disease activity…
Abstract Number: 2393 • 2014 ACR/ARHP Annual Meeting
Similar Improvements in Physical Function, Quality of Life and Work Productivity Among Rheumatoid Arthritis Patients Treated with 2 Different Doses of Methotrexate in Combination with Adalimumab
Gurjit S. Kaeley¹, Midori Jane Nishio², Daryl MacCarter³, Jenny Griffith⁴, Hartmut Kupper⁵, Vishvas Garg⁶ and Jasmina Kalabic⁵, ¹College of Medicine, University of Florida, Jacksonville, FL, ²Diablo Clinical Research, Walnut Creek, CA, ³Coeur d'Alene Arthritis Clinic, Coeur d'Alene, ID, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose Methotrexate (MTX) is used in monotherapy or in combination with other DMARDs in the treatment of patients (pts) with rheumatoid arthritis (RA). We evaluated…
Abstract Number: 490 • 2014 ACR/ARHP Annual Meeting
A Randomised Controlled Trial Evaluating the Effect of Humira upon Endothelial Function in ACPA Positive Rheumatoid Arthritis â€“ an Interim Analysis
Stephen Oakley^1,2,3, Niloofar Esmaili⁴, Gabor Major⁴, David Mathers^4,5, Siva Ratnarajah⁶, John van der Kallen⁵, Mark Collins⁶, Marc Toh⁶ and John Glass⁴, ¹Dept of Rheumatology, Newcastle Bone & Joint Institute, Newcastle, Australia, ²School of Medicine & Public Health, University of Newcastle, Newcastle, Australia, ³Clinical Trials Unit, Hunter Medical Research Institute, Newcastle, Australia, ⁴Rheumatology, Newcastle Bone & Joint Institute, Newcastle, Australia, ⁵Rheumatology, Georgetown Arthritis Centre, Newcastle, Australia, ⁶Rheumatology, Private Practice, Newcastle, Australia
Background/Purpose Rheumatoid arthritis (RA) is associated with elevated cardiovascular (CV) risk not explained by traditional risk factors. Increased CV risk may develop prior to the…
Abstract Number: 2043 • 2014 ACR/ARHP Annual Meeting
How Correct Are the Assumptions Made for Tuberculosis Screening Algorythms before TNF-Alpha Antagonists?
Aysa Hacioglu¹, Yesim Ozguler², Sermin Borekci³, Vedat Hamuryudan¹, Hanefi Deniz Kecebas¹, Ethem Koray Tascilar², Melike Melikoglu⁴, Serdal Ugurlu¹, Emire Seyahi¹, Izzet Fresko², Huri Ozdogan¹, Sebahattin Yurdakul¹, Gul Ongen³ and Gulen Hatemi¹, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ³University of Istanbul, Cerrahpasa Medical Faculty, Department of Pulmonary Diseases, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose: During the development of algorythms for screening latent tuberculosis before starting TNF-alpha antagonists, it is assumed that BCG vaccination causes false positive PPD and…
Abstract Number: 285 • 2014 ACR/ARHP Annual Meeting
Drug Safety in Treatment of Juvenile Idiopathic Arthritis (JIA): Biologic Therapy Compared with MTX
Gerd Horneff¹, Hans Huppertz², Gerd Ganser³, Johannes Peter Haas⁴, Ivan Foeldvari⁵ and Kirsten Minden⁶, ¹Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ²Prof Hess Children’s Hospital, Bremen, Germany, ³Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ⁴German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ⁵Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁶Epidemiology unit, German Rheumatism Research Center, Berlin, Germany
Background/Purpose Drug surveillance of biologics in juvenile patients using registries is of immense importance as patient numbers and duration in clinical trials are limited. There…
Abstract Number: 1843 • 2014 ACR/ARHP Annual Meeting
Randomised Controlled Non-Inferiority Study of Dose Reduction and Withdrawal of Adalimumab and Etanercept in Rheumatoid Arthritis
Noortje van Herwaarden¹, Aatke van der Maas¹, Michiel Minten¹, Frank H.J. van den Hoogen², Ronald F. van Vollenhoven³, Johannes W.J. Bijlsma⁴, Bart van den Bemt⁵ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ³Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose TNF inhibitors (TNFi) have proven to be effective in the treatment of rheumatoid arthritis (RA). They are however associated with side effects and high…
Abstract Number: 289 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis Who Are Prescribed and Treated with Adalimumab
Gerd Horneff¹, Carol A. Wallace², Pierre Quartier³, Daniel J. Kingsbury⁴, Kirsten Minden⁵, Mareike Bereswill⁶, Vishvas Garg⁷, Hartmut Kupper⁶ and Jasmina Kalabic⁶, ¹Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ²University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ³Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ⁴Randall Children's Hospital at Legacy Emanuel, Portland, OR, ⁵Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁷AbbVie Inc., North Chicago, IL
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood and adolescents, and improvement in health-related quality of life and…
Abstract Number: 1443 • 2013 ACR/ARHP Annual Meeting
Is The Risk Of Tumor Necrosis Factor Inhibitor-Induced Lupus The Same With Monoclonal Antibodies and Soluble Receptor? A Case/Non-Case Study In a Nationwide Pharmacovigilance Database
Guillaume Moulis¹, Agnès Sommet², Maryse Lapeyre-Mestre² and Jean-Louis Montastruc², ¹Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, France, ²Department of Clinical Pharmacology, Toulouse University Hospital, INSERM U1027, University of Toulouse, France, Toulouse, France
Background/Purpose: Albeit lupus occurring on each TNFi have been reported, no epidemiological study has been conducted to assess the link between lupus onset and each…
Abstract Number: 450 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy Compared With Adalimumab Monotherapy In Patients With Rheumatoid Arthritis: An Evaluation Of High-Density Lipoprotein Composition
Cem Gabay¹, Katie Tuckwell², Jennifer Green², Micki Klearman³ and Arthur Kavanaugh⁴, ¹SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, ²Roche, Welwyn Garden City, United Kingdom, ³Roche, South San Francisco, CA, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) patients (pts) are at increased risk for cardiovascular (CV) disease. Although analysis of lipids such as LDL-C and HDL-C is useful…
Abstract Number: 157 • 2013 ACR/ARHP Annual Meeting
Application Of a Multiplex Gene Polymorphism Assay For Variants Associated With Rheumatoid Arthritis Susceptibility: Results Of 168 Single Nucleotide Polymorphisms In The Optima Study
Jeffrey F. Waring¹, Viswanath Devanarayan², Kenneth Idler¹, Feng Hong², Josef S. Smolen³, Arthur Kavanaugh⁴, Hartmut Kupper⁵, Hendrik Schulze-Koops⁶ and Alla Skapenko⁷, ¹AbbVie Inc., North Chicago, IL, ²AbbVie Bioresearch Center, Worchester, MA, ³Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴University of California San Diego, La Jolla, CA, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁶Division of Rheumatology, University of Munich, Munich, Germany, ⁷Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany
Background/Purpose: Genetic factors have been identified that may be associated with the development and severity of rheumatoid arthritis (RA), disease progression, or response to treatment.…
Abstract Number: 1423 • 2013 ACR/ARHP Annual Meeting
The Influence Of Body Mass Index On The Efficacy Of Tumor Necrosis Factor Blocking Therapy For Rheumatoid Arthritis
Ingrid M. Visman¹, Inge A.M. van den Oever¹, Charlotte L. M. Krieckaert¹, Gertjan Wolbink¹ and Michael T. Nurmohamed², ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²VU University Medical Center & Jan van Breemen Research Institute, Amsterdam, Netherlands
Background/Purpose : The impact of Body mass Index (BMI) on efficacy of TNF blocking therapy is an important question, as adipose tissue appears to have…
Abstract Number: 425 • 2013 ACR/ARHP Annual Meeting
Efficacy, Pharmacokinetics, and Safety of Different Doses of Methotrexate in Combination With Adalimumab: Results From the Concerto Trial
Gerd Burmester¹, Alan J. Kivitz², Hartmut Kupper³, Udayasankar Arulmani⁴, Stefan Florentinus⁵, Sandra Goss⁴, Suchitrita S. Rathmann⁴ and Roy Fleischmann⁶, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Altoona Center for Clinical Research, Duncansville, PA, ³AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie, Rungis, France, ⁶University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Anti-TNF plus methotrexate (MTX) is more effective than either as monotherapy. Thus far, no controlled data are available on the benefit:risk of different doses…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].